Dear Colleagues,

Antibody drug conjugates (ADCs) are a promising class of biotherapeutics for the treatment of diseases, such as cancer. Pairing potent drugs with antibodies through covalent attachment generates a unique therapeutic molecule, where the antibody provides cell-selectivity and extended serum half-life, while the drug provides a potent inhibitor of metabolism. “Piggybacking” potent small molecule drugs onto large antibody carriers has allowed new drugs to be used for cancer treatment (such as auristatins, tubulysins, PBDs, and duocarmycins) that present challenges as small molecule therapies alone. Recently fueled by the clinical success of Kadcyla and Adcetris.

This Special Issue of *Antibodies* focuses on recent advances in ADC technology, including drug-linker design, warhead selection, conjugation approaches, antibody engineering, target selection, clinical manifestation, and other aspects related to ADCs.

Dr. R. James (Jim) Christie

*Guest Editor*
Editor-in-Chief

Prof. Dr. Dimiter S. Dimitrov
Center for Antibody Therapeutics, University of Pittsburgh Medical School, Pittsburgh, PA 15213, USA

Message from the Editor-in-Chief

Antibodies is a relatively new journal with a major focus on quick dissemination of knowledge related to antibodies, especially how to quickly translate basic research results to therapeutic applications. Because it covers all areas related to antibodies unexpected connections between different areas could be made, leading to major discoveries and opening new fields of research and development. This is enhanced by the large readership of the many antibody-related areas of research. A specific priority area is human monoclonal antibodies for therapy of diseases and aging.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High visibility: Indexed in the Emerging Sources Citation Index (ESCI - Web of Science), EMBASE (Elsevier) and other databases. Full-text archived in PubMed Central; citations to become available in Pubmed soon.

Rapid publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 6.8 days (median values for papers published in this journal in the first half of 2019).

Contact Us

Antibodies
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland
Tel: +41 61 683 77 34
Fax: +41 61 302 89 18
www.mdpi.com

antibodies@mdpi.com

mdpi.com/journal/antibodies